Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | GLA | P06280 | 5/20 | 0.49 |
| ▸ | GAA | P10253 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | USP7 | Q93009 | 4/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL832455 | 0.75 | KDM4E (0.47) | KDM4EALDH1A1GLAGAASMN1; SMN2 | |
| SCHEMBL839837 | 0.75 | ALDH1A1 (0.62) | KDM4EALDH1A1GLAGAASMN1; SMN2 | |
| SCHEMBL23294847 | 0.74 | KDM4E (0.46) | KDM4EALDH1A1GLAGAASMN1; SMN2 | |
| SCHEMBL7794403 | 0.72 | KDM4E (0.49) | KDM4EALDH1A1GLAGAASMN1; SMN2 | |
| SCHEMBL15437780 | 0.69 | SMN1; SMN2 (0.44) | KDM4EALDH1A1GAASMN1; SMN2HPGD | |
| SCHEMBL22342347 | 0.68 | SMN1; SMN2 (0.36) | KDM4EALDH1A1GAASMN1; SMN2HPGD | |
| SCHEMBL15641745 | 0.67 | KDM4E (0.47) | KDM4EALDH1A1GLAGAASMN1; SMN2 | |
| SCHEMBL8311753 | 0.67 | ALDH1A1 (0.50) | KDM4EALDH1A1GLAGAASMN1; SMN2 | |
| SCHEMBL2427657 | 0.66 | KDM4E (1.00) | KDM4EALDH1A1GLAGAASMN1; SMN2 | |
| SCHEMBL5573020 | 0.66 | PTPN1 (0.49) | KDM4EALDH1A1GLAGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999741-B2 | Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | CARDURION PHARMACEUTICALS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| EP-3630772-B1 | METHODS OF MAKING AND USING PDE9 INHIBITORS | IMARA INC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20230183244-A1 | METHODS OF MAKING AND USING PDE9 INHIBITORS | CARDURION PHARMACEUTICALS, INC. | 2023-06-15 | — | — | US | disclosed |
| US-11370795-B2 | Process for the synthesis of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | Imara Inc. (US) | 2022-06-28 | — | — | US | disclosed |
| US-20220185836-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF CANCERS | XLINK THERAPEUTICS INC (US) | 2022-06-16 | — | — | US | disclosed |
| EP-3157515-B1 | PLATINUM COMPOUNDS, COMPOSITIONS, AND USES THEREOF | PLACON THERAPEUTICS INC (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3797768-A1 | MALEIMIDE-FUNCTIONALISED PLATINUM FOR USE IN THE TREATMENT OF CANCER | Placon Therapeutics, Inc. (US) | 2021-03-31 | — | — | EP | disclosed |
| US-20210085684-A1 | PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES | CARDURION PHARMACEUTICALS, INC. | 2021-03-25 | — | — | US | disclosed |
| EP-3313392-B1 | PLATINUM COMPOUNDS, COMPOSITIONS, AND USES THEREOF | PLACON THERAPEUTICS INC (US) | 2020-09-16 | — | — | EP | disclosed |
| US-20200157108-A1 | METHODS OF MAKING AND USING PDE9 INHIBITORS | CARDURION PHARMACEUTICALS, INC. | 2020-05-21 | — | — | US | disclosed |
| EP-2125811-A2 | N-(AMINO-HETEROARYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDES DERIVATIVES, PREPARATION THEREOF AND THEIR USE IN THERAPY | Sanofi-Aventis (FR) | 2009-12-02 | — | — | EP | disclosed |
| EP-2125787-A1 | DERIVATIVES OF N-(HETEROARYL)-1-HETEROARYL-1H-INDOL-2-CARBOXAMIDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2009-12-02 | — | — | EP | disclosed |
| WO-2009109710-A1 | DERIVATIVES OF INDOLE 2-CARBOXAMIDES AND AZAINDOLE 2-CARBOXAMIDES SUBSTITUTED BY A SILANYLE GROUP, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-09-11 | — | — | WO | disclosed |
| US-20090042873-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-02-12 | — | — | US | disclosed |
| WO-2008107544-A1 | DERIVATIVES OF N-(HETEROARYL)-1-HETEROARYL-1H-INDOL-2-CARBOXAMIDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008093024-A2 | N-(AMINO-HETEROARYL)-1H-PYRROLOPYRIDINE-2-CARBOXAMIDES DERIVATIVES, PREPARATION THEREOF AND THEIR USE IN THERAPY | SANOFI-AVENTIS (FR) | 2008-08-07 | — | — | WO | disclosed |
| US-20080044354-A1 | Compounds Containing a N-Heteroaryl Moiety Linked to Fused Ring Moieties for the Inhibition of Nad(P)H Oxidases and Platelet Activation | VASOPHARM GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| EP-1756113-A1 | COMPOUNDS CONTAINING A N-HETEROARYL MOIETY LINKED TO FUSED RING MOIETIES FOR THE INHIBITION OF NAD(P)H OXIDASES AND PLATELET ACTIVATION | Vasopharm Biotech GmbH (DE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005111041-A1 | COMPOUNDS CONTAINING A N-HETEROARYL MOIETY LINKED TO FUSED RING MOIETIES FOR THE INHIBITION OF NAD(P)H OXIDASES AND PLATELET ACTIVATION | VASOPHARM BIOTECH GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| EP-1598354-A1 | Compounds containing a N-heteroaryl moiety linked to fused ring moieties for the inhibition of NAD(P)H oxidases and platelet activation | Vasopharm Biotech GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185836-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF CANCERS | TP53, VHL, KRAS | KDM4E 1824/4885ALDH1A1 2098/4885GLA 3247/4885 |
| US-20210085684-A1 | PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES | PDE9A, PDE12, PDE5A | KDM4E 3503/4885ALDH1A1 1037/4885GLA 904/4885 |
| US-20200157108-A1 | METHODS OF MAKING AND USING PDE9 INHIBITORS | PDE9A, PDE2A, PDE3B | KDM4E 1993/4885ALDH1A1 560/4885GLA 227/4885 |
| US-20090042873-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | CYP3A5, CYP2C8, PAICS | KDM4E 1797/4885ALDH1A1 484/4885GLA 2541/4885 |
| US-11999741-B2 | Process for the synthesis of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-3-(tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | CDK8, PRMT8, RPS8 | KDM4E 969/4885ALDH1A1 2636/4885GLA 4010/4885 |
| US-20230183244-A1 | METHODS OF MAKING AND USING PDE9 INHIBITORS | PDE9A, PDE4B, PDE12 | KDM4E 2462/4885ALDH1A1 2125/4885GLA 175/4885 |
| US-20080044354-A1 | Compounds Containing a N-Heteroaryl Moiety Linked to Fused Ring Moieties for the Inhibition of Nad(P)H Oxidases and Platelet Activation | NQO1, CYBB, NADK | KDM4E 2395/4885ALDH1A1 284/4885GLA 1454/4885 |
| US-11370795-B2 | Process for the synthesis of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one | TYMS, TKT, TPMT | KDM4E 1156/4885ALDH1A1 648/4885GLA 3152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.